Skip to main content
. 2012 Dec 18;121(8):1394–1402. doi: 10.1182/blood-2012-08-452284

Table 2.

Clinical data of 40 cyclin D1− MCL patients

ID Translocation Age, y/sex LN involvement Extranodal LDH Stage IPI Therapy Response OS
ID13,12,22,23 Negative 54/F LN (inguinal) Intestine Normal IIIA 1 CHOP CR 60+
ID23,12,22,23 Negative 61/M LN (multiple) PB, BM High IV 3 R-CHOP PR 11
ID33,12,22,23 Negative 61/M LN BM Normal IV 2 CHOP PR 88
ID43,12,22,23 Negative 60/M LN (multiple) PB, BM, spleen High IV 3 COP+FCR PR 26
ID53,12,22,23 Negative 54/M LN BM Normal IV 2 CHOP PR 70+
ID63,12,22,23 Negative 77/M LN BM Normal IV 3 C PR 101
ID712 D2-K 56/M LN (inguinal) BM, liver High IVB 2 CEOP - 25
ID812 Negative 60/M No Colorectal* - IIAE - R-CHOP PR 67+
ID912 Negative 52/F LN BM Normal IVA - R-CHOP CR 84+
ID1012 D2-K 70/F LN Tonsil Normal IIIE - R-CHOP PR 37
ID1112 Negative 39/M LN (multiple) PB, BM High IV 2 R-CHVmP/BO PR 24
ID1212 Negative 68/M LN (inguinal) No Normal IA 1 R-CHOP+RT CR 71
ID134,7 D2-K 70/M LN (multiple) BM - IVB - - - -
ID146,7 D2-H 52/M LN (multiple) BM, GI tract - IV - - - -
ID157 D2-K 82/F LN (cervical) Waldeyer ring, tonsil - IIIB - - - 15
ID167 D2-? 59/M LN (multiple) BM, spleen - IV - R-CHOP CR 118+
ID174 D2-K 33/F LN (cervical) BM, duodenum, colon - IVA - - - -
ID188 D2-K 65/M LN BM, PB, tonsil - IVB - CT and RT PD 15
ID238 Negative 42/M LN BM, CNS - IVB - CHOP CR 37
ID24 D2-H 69/M LN (cervical) BM, PB, Waldeyer ring, tongue High IVB 4 Hyper-CVAD regimen, gemcitabine/oxaliplatin CR 6+
ID25 Negative 60/F LN (cervical) - - - - - CR 21+
ID26 Negative 71/F LN (inguinal) BM, spleen High IV - R-CHOP PR 7
ID27 Negative 78/M LN (inguinal) No Normal IIIA - None - 12+
ID28 D2-K 72/M LN (inguinal) BM, PB - IV ≥ 3 - - -
ID29 D2-break 77/M LN (cervical) BM, PB - IV - R, Bendamustine NR -
ID30 Negative 54/M LN (axillary) BM, PB Normal IVA 2 R PD 2+
ID31 D2-break 77/M LN (periaortic) BM High IVA 2 R-CHOP CR 22+
ID32 D2-K 73/M LN (axillary) BM - IV - None - 4
ID33 Negative 78/M LN Parotid Normal IV 2 R-CHOP CR 38+
ID34 D2-? 60/F LN BM, PB Normal IV 2 R-CHOP, RDHAP, BMT CR 22+
ID35 D2-L 56/M LN (multiple) BM, PB, spleen - IV - FCR - 12
ID36 D2-L 90/F LN (mutiple) BM, spleen - - - - - 15
ID37 D2-L 60/M LN (mutiple) BM, tonsil Normal IV - FC CR 39
ID38 Negative 51/M LN (mutiple) BM, spleen, tonsil Normal III - R-CHOP - 3+
ID39 D2-L 90/M LN (cervical) Tonsil - IIA - R-COP PR 14
ID40 D2-K 64/M LN (multiple) BM, spleen, pleura High IV 3-4 R-CHOP PD 3.5
ID42 D2-L 54/F LN (inguinal) Stomach Normal IIA 0 R CR 64+
ID43 D2-H 73/M LN (mediastinal, subcranial) Lung - Low - Involved field radiation - 109+
ID44 D2-K 54/M LN (inguinal) BM Normal IVA - R-CHOP CR 60+
ID46 Negative 56/F - Colonic mucosa* - - - - - -

B indicates bleomycin; BMT, BM transplantation; C, cyclophosphamide; CR, complete remission; CT, chemotherapy not specified; D2-?, CCND2 break with unidentified partner discarding IGH@, IGK@, and IGL@; D2-break, CCND2 break with unidentified partner; E, etoposide; F, fludarabine; H, Adriamycin; IPI, International Prognostic Index; LDH, lactate dehydrogenase; LN, lymph node; O, vincristine; P, prednisone; PB, peripheral blood; PD, progressive disease; PR, partial response; R, rituximab; RT, radiotherapy; T, treatment; Vm, teniposide; +, alive; and -, not available.

*

Multiple intestinal lymphomatous polyposis.

HHS Vulnerability Disclosure